Reduced-dose Alemtuzumab for Kidney Transplant Rejection

Launched by ERASMUS MEDICAL CENTER · Oct 20, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called alemtuzumab, which is used to help prevent kidney transplant rejection, especially in patients who have experienced severe rejection or have not responded to standard treatments. The study aims to see if using a lower dose of alemtuzumab can still be effective and safe for these patients. Researchers are currently recruiting participants who are at least 18 years old and have been treated for severe kidney transplant rejection with alemtuzumab.

To join the study, participants should not have received certain other treatments for rejection before starting alemtuzumab, and they should have a specific level of immune cells in their blood. Those who take part in the trial will receive the reduced-dose treatment and will be monitored closely to see how well it works and what effects it has. This study is important because it could help improve the way kidney transplant rejection is managed, potentially making treatment safer and more effective for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Treatment for severe or glucocorticoid-resistant kidney transplant rejection with alemtuzumab.
• Exclusion Criteria:
• • Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to treatment with alemtuzumab for the same rejection episode.
• • Recipients who have T cell counts below 200 × 106/L before the start of therapy (for instance, because of lymphocyte depleting induction therapies).
• • Inability to provide written informed consent